TABLE 2.
Primary outcomes of the COVID‐19 patients
| Primary outcomes | Participants | p‐value* | ||
|---|---|---|---|---|
| Control (n = 21) | Intervention (n = 19) | Total (n = 40) | ||
| Admission days1 | 7 (4) | 5 (6) | 5.5 (5) | .42 |
| ICU | ||||
| No | 19 (90.5%) | 17 (89.5) | 36 (90%) | p > .05 |
| Yes | 2 (9.5%) | 2 (10.5%) | 4 (10%) | |
| Additional therapies | ||||
| Hemoperfusion (×3) | 1 (4.8%) | 0 | 1 (2.5%) | .46 |
| Interferon 1‐β | 0 | 1 (5.3%) | 1 (2.5%) | |
| Methylprednisolone (500 mg) | 0 | 1 (5.3%) | 1 (2.5%) | |
| Intubation | ||||
| No | 21 (100%) | 19 (100%) | 40 (100%) | — |
| Yes | 0 | 0 | 0 | |
| Re‐admitted patients | ||||
| No | 16 (76.2%) | 19 (100%) | 35 (87.5%) | .04 |
| Yes | 5 (23.8%) | 0 | 5 (12.5%) | |
1Data are shown as median [interval quartile (IQR)], *: Chi‐square or fisher's exact test was applied and p‐value<.05 was considered statistically significant.